CN Bio
CN Bio is a leading organ-on-a-chip (OOC) company based in Cambridge, UK. CN Bio offers a portfolio of products and services to optimise the accuracy and efficiency of bringing new medicines to market; providing significant savings in cost and time to drug discovery and development pipelines.With more than a decade of experience in precision engineering and single and multi-organ microphysiology, CN Bio aims to transform the way human-relevant pre-clinical data is generated through the development of advanced, predictive human organ models. The Company’s PhysioMimix® OOC range of microphysiological systems (MPS) bridges the relevance gap between traditional cell culture, in vivo animal studies, and human trials by advancing towards the simulation of human biological conditions. The technology provides deep mechanistic insights to enable researchers to refine preclinical study design, reducing the number of animals required, and better preparing and informing studies ahead of the clinic to support safe, efficacious and efficient therapeutic development.Content by CN Bio
| 5 min read
New modality drugs offer promising therapeutic approaches to address unmet medical needs – but not without challenges.
Discover how human-relevant models improve the understanding of drug delivery, efficacy, and safety.
Page 1 of 1 - 2 Total Items
Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
SubscribeSponsored
Enhancing bioanalytical studies with centralized data management
Learn how researchers can improve compliance and efficiency with advanced LIMS solutions.
Explained: How are metabolite biomarkers improving drug discovery and development?
By offering a rich source of insights into disease and drugs, metabolite biomarkers are at the forefront of therapeutic exploration.
Supercharging cell line development and engineering with automated single cell sorting
Researchers can enhance efficiency, yield, and consistency in clonal cell line development with specialized tools.
